International Breast Cancer Study Group Release: Web Cast Of Landmark, Independent Trial Data From Major Breast Cancer Meeting

ST. GALLEN, Switzerland, Jan. 26 /PRNewswire/ --

WHAT: BIG 1-98: First results and implications. A landmark, independent study found that letrozole, a leading aromatase inhibitor also known as Femara, demonstrated better efficacy in reducing the risk of recurrence for breast cancer compared with the current standard of care, tamoxifen. Significant findings include: * Letrozole reduced the risk of breast cancer recurrence by 19% compared with tamoxifen * Letrozole significantly prolonged disease free survival compared with tamoxifen * Letrozole reduced the risk of breast cancer mestasis by 27% compared with the reduction offered by tamoxifen This Web cast offers a presentation of the BIG 1-98 trial results presented at the Primary Therapy of Early Breast Cancer 9th International Conference in St. Gallen, Switzerland and an understanding of what the trial results mean for patients. BIG 1-98 is an independent Phase III, randomized, double-blind, controlled clinical trial of more than 8,000 postmenopausal women with early breast cancer from 27 countries WHEN: 1:05 pm ET / 7:05 pm. CET, Wednesday, 26 January WHERE: Click on the following link and view the Web cast data presentation: http://www.ibcsg.org/index.shtm WHO: PD Beat Thurlimann, M.D., Scientific Secretary General, Primary Therapy of Early Breast Cancer, Head of the Senology Center of Eastern Switzerland, Kantonsspital St. Gallen, Presentation of the BIG 1-98 Trial Results CONTACTS: For questions or to arrange an interview with PD Beat Thurlimann, please contact: Rum Ekhtiar Nadia Munarini, PhD Ruder Finn IBCSG Tel. +1.212.593.5821 Tel. +41.31.389.92.27 ekhtiarr@ruderfinn.comnadia.munarini@ibcsg.org

CONTACT: Nadia Munarini, PhD, IBCSG, +41-31-389-92-27, ornadia.munarini@ibcsg.org; Rum Ekhtiar of Ruder Finn, +1-212-593-5821, orekhtiarr@ruderfinn.com, for IBCSG

Web Site: http://www.ibcsg.org/index.shtm